Synthesis of polymer nanoparticles sensitive to pH for DNA delivery in intracellular environment by Lopes, Eduardo
 
 
Universidade do Algarve 
Departamento de Ciências Biomédicas e Medicina 
 
 
 
Synthesis of polymer nanoparticles 
sensitive to pH for DNA delivery in intracellular 
environment 
 
 
 
 
 
Eduardo Manuel da Fonseca Lopes 
 
Mestrado em Ciências Biomédicas 
 
 
 
Faro, Setembro de 2011 
 
 
Universidade do Algarve 
Departamento de Ciências Biomédicas e Medicina 
 
 
 
Synthesis of polymer nanoparticles 
sensitive to pH for DNA delivery in intracellular 
environment 
 
 
Dissertation supervised by: Prof. Dra. Ana Costa 
Dissertion co-supervised by: Prof. Dra. Gabriela Silva 
 
Eduardo Manuel da Fonseca Lopes 
 
Mestrado em Ciências Biomédicas 
 
 
 
Faro, Setembro de 2011 
 
 
Index 
 
Acknowledgements ...........................................................................................................i 
Abbreviations .................................................................................................................... ii 
Abstract ............................................................................................................................ iv 
Resumo .............................................................................................................................. v 
I – Introduction ................................................................................................................ 1 
II – Materials and methods ............................................................................................ 13 
2.1 – Synthesis of PDMAEMA ..................................................................................... 13 
2.2 – 1H NMR spectroscopy ........................................................................................ 13 
2.3 – Gel permeation chromatography ...................................................................... 14 
2.4 – FTIR spectroscopy .............................................................................................. 14 
2.5 – Potentiometric titration ..................................................................................... 14 
2.6 – Cell culture ......................................................................................................... 15 
2.7 – Cell viability assay .............................................................................................. 15 
2.8 – Dynamic light scattering and zeta potential measurements of PDMAEMA/pDNA 
polyplexes ................................................................................................................... 16 
2.8.1 – Polyplex preparation ................................................................................... 16 
2.8.2 – DLS and zeta potential measurements ....................................................... 17 
2.9 – DNA gel shift assay ............................................................................................. 17 
2.10 – DNase I protection assay.................................................................................. 18 
2.11 – DNA release assay from PDMAEMA/pDNA polyplexes ................................... 19 
2.12 – In vitro transfection assay ................................................................................ 19 
III – Results ..................................................................................................................... 21 
3.1 – 1H NMR spectroscopy ........................................................................................ 21 
3.2 – Gel permeation chromatography ...................................................................... 22 
3.3 – FTIR spectroscopy .............................................................................................. 23 
3.4 – Potentiometric titration ..................................................................................... 24 
3.5 – Cell viability assay .............................................................................................. 25 
3.6 – Determination of PDMAEMA/pDNA polyplexes size and zeta potential .......... 29 
3.7 – DNA gel shift assay ............................................................................................. 30 
3.8 – DNase I protection assay.................................................................................... 31 
 
 
3.9 – DNA release assay from PDMAEMA/pDNA polyplexes ..................................... 32 
3.10 – In vitro transfection assay ................................................................................ 33 
IV – Discussion................................................................................................................ 40 
V – Conclusion and future perspectives ........................................................................ 44 
VI – Bibliography ............................................................................................................ 46 
 
 
 
 
 
 
i 
 
Acknowledgements 
 
I would like to thank the following people: 
 
My supervisors Prof. Ana Costa, PhD and Prof. Gabriela Silva, PhD which 
granted me an opportunity to be working in this project. Without their endless support 
it would be impossible to travel the long road that was this work. 
 
My co-workers Vanessa, Andreia, Susana, Sofia, Solé and Jorge for their 
fellowship and invaluable support in the laboratory. 
 
 My fiends, for being a ray of light when all hope seemed to be lost. 
 
 And last but not least, my family for their unconditional support and care. 
 
 
 
 
 
 
 
 
ii 
 
Abbreviations 
 
AIBN – 2,2'-azobisisobutyronitrile; 
CTA – chain transfer agent; 
DMAEMA – 2-(N,N’-dimethylamino)ethyl methacrilate; 
DMEM – Dulbecco’s Modified Eagle Medium; 
EDTA – ethylenediamine tetraacetic acid; 
FACS – fluorescence activated cell sorting; 
FBS – fetal bovine serum; 
GFP – green fluorescent protein; 
GPC – gel permeation chromatography; 
HEK293 – Human Embryonic Kidney 293; 
Mn – number-average molecular weight; 
MTT – 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide; 
Mw – weight-average molecular weight; 
N/P – nitrogen/phosphorus; 
NVP – N-vinyl-pyrrolidone; 
OD – optical density; 
PAMAM – polyamidoamine; 
PBS – phosphate buffer saline; 
PDI – polydispersity index; 
pDNA – plasmid DNA; 
iii 
 
PEG – polyethylene glycol; 
PEI – polyethylenimine; 
PDMAEMA – poly(2-(N,N’-dimethylamino)ethyl methacrilate); 
PLL – poly(L-lysine); 
RAFT – reversible addition−fragmentation chain transfer polymerization; 
RPE – retinal pigment epithelium; 
siRNA – small interfering RNA; 
TBE – Tris/Borate/EDTA; 
THF – tetrahydrofuran; 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
Abstract 
 
 Gene therapy is a potentially great therapeutic approach for a wide range of 
diseases. Consequently, it is critical to develop adequate delivery vectors. In this study, 
we evaluated if poly(2-(N,N’-dimethylamino)ethyl methacrilate) (PDMAEMA), which 
proved to be an efficient delivery vector for OVCAR-3 cells, is also suitable to transport 
nucleic acids to the retina. In this regard, reversible addition-fragmentation chain 
transfer polymerization (RAFT) was used to synthesize PDMAEMA with a weight-
average molecular weight (Mw) of 200 kDa. H
1 NMR and Fourier transform infrared 
(FTIR) spectroscopy confirmed the chemical structure of the polymer and 
potentiometric titration showed that PDMAEMA has a pKa value around 7. However, 
gel permeation chromatography (GPC) analysis revealed that the polymer obtained 
had a Mw of 354 kDa. The cytotoxicity of PDMAEMA was evaluated in retinal pigment 
epithelium (RPE) cell lines ARPE-19 and D407, as well as in Human Embryonic Kidney 
293 (HEK293) cells and was found to be proportional to polymer concentration. 
However, for the concentration to be used in vivo, the cytotoxicity was negligible. 
Polyplexes of polymer/DNA with nitrogen/phosphorus (N/P) ratios of 5 and 10 were 
able to encapsulate and protect DNA from DNase action. Dynamic light scattering (DLS) 
and zeta potential measurements revealed nanosized particles with sizes around 213 
nm with acceptable polydispersity indexes (PDI) and positive surface charges with 
magnitudes around 18mV. Fluorescence microscopy showed all three cell lines were 
efficiently transfected with these polyplexes, although to a lesser extent in RPE cells. 
However, preliminary evaluation of transfection efficiency by flow citometry, did not 
seem to reflect the effectiveness of the polymer in terms of cell transfection 
Altogether these results suggest that PDMAEMA is a good candidate as a non-
viral delivery vector for gene therapy of the retina. 
 
Keywords: Gene therapy, delivery vectors, RAFT, PDMAEMA, RPE. 
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Resumo 
 
Nos últimos anos, a terapia génica tem sido estudada como uma potencial 
abordagem para o tratamento de doenças de base genética. Este tipo de abordagem 
envolve o uso de plasmídeos, oligonucleótidos, ribozimas, entre outros, como um meio 
de modular a expressão genética e, consequentemente, gerar um efeito terapêutico. 
A célula apresenta várias barreiras à inserção de material genético no seu 
interior tais como a membrana celular, o sistema endossomal e a membrana nuclear. 
Posto isto, é crítico desenvolver métodos de entrega de DNA eficientes para que a 
terapia génica possa atingir todo o seu potencial. 
Em terapia génica, inicialmente foram utilizados métodos mecânicos e 
eléctricos para inserção do DNA no interior das células, recorrendo-se a estratégias 
como microinjecção, bombardeamento de partículas, pressão e eletroporação. Não 
obstante a enorme eficiência de transfeção destas técnicas, são contudo invasivas, 
laboriosas e difíceis de aplicar num cenário clínico. 
Face a estes constrangimentos, desenvolveram-se outras técnicas de entrega 
de material genético envolvendo o uso de vectores, dividindo-se estes em duas 
categorias: vectores de entrega virais e vectores de entrega não virais. Um vector de 
entrega deve possuir características tais como ser biodegradável, pouco tóxico e 
imunogénico, poder constituir uma formulação farmacêutica estável e ser altamente 
eficiente e específico no processo de transfecção. 
Milhões de anos de evolução tornaram os vírus em agentes infecciosos 
bastante eficientes, deste modo, vectores de entrega virais compreendem a aplicação 
de vírus tais como retrovírus, adenovírus, lentivírus, entre outros. A grande vantagem 
de recorrer a vírus como vectores de entrega de material genético é a elevada 
eficiência de transfecção resultante. No entanto, o uso de vectores virais pode 
desencadear resposta imunitária e/ou levar à potencial integração aleatória dos genes 
terapêuticos no genoma do hospedeiro, com consequências bastante negativas. Deste 
modo, o foco de atenção tem incidido na aplicação de vectores de entrega não virais 
numa óptica de contornar as desvantagens apresentadas. 
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Por sua vez, os vectores de entrega não virais podem ser categorizados em 
sistemas de entrega lipossomais ou poliméricos. 
 Os vectores de entrega lipossomais utilizados em terapia génica são 
numerosos, podendo ser catiónicos, aniónicos, sensíveis ao pH, camuflados ou 
imunolipossomas. No geral, a grande vantagem em se recorrer a este tipo de vectores 
é a baixa imunogenicidade dos lipossomas e a facilidade com que são manipuláveis a 
nível de formulação, sendo possível produzir lipossomas com características bastante 
definidas em termos de tamanho, carga de superfície, composição e morfologia. No 
entanto, apresentam desvantagens como citotoxicidade e pouca estabilidade. 
 Os vectores de entrega poliméricos geralmente envolvem o uso de polímeros 
catiónicos uma vez que estes são capazes de complexar o DNA carregado 
negativamente por intermédio de interacções electrostáticas entre as cargas positivas 
presentes no polímero e os grupos fosfato na presentes na estrutura das moléculas de 
DNA, formando-se assim complexos denominados de poliplexos. Esta abordagem 
engloba o uso de polímeros como dendrímeros, PEI, PDMAEMA e quitosano. As 
vantagens mais importantes apresentadas por esta abordagem são a versatilidade de 
propriedades físico-químicas e facilidade de manipulação características dos 
polímeros. 
 Dendrímeros tais como a PAMAM, apresentam vantagens a nível do controlo 
da sua síntese, sendo possível produzir polímeros bastante monodispersos, o que 
resulta numa elevada reprodutibilidade na entrega de material genético. 
 Um dos polímeros mais estudados em terapia génica é o PEI. Trata-se de um 
polímero caracterizado pelo seu enorme potencial catiónico, traduzindo-se em 
elevadas eficiências de transfecção. A enorme desvantagem deste polímero é a sua 
elevada toxicidade, sendo que se desenvolveram estratégias de modo a amenizar esta 
característica. 
 Uma alternativa bastante viável ao PEI é o PDMAEMA. Este polímero catiónico 
solúvel em água também é capaz de interagir eletrostaticamente com o DNA de modo 
a formar poliplexos. Vários estudos demonstraram que a eficiência de transfecção 
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deste polímero é proporcional ao seu peso molecular. Este polímero apresentou uma 
elevada eficiência de transfecção in vitro (cerca de 10%) quando avaliado em células 
OVCAR-3.  
 Para além dos polímeros sintéticos apresentados, os polímeros naturais como o 
quitosano são bastante apelativos para aplicações em terapia génica devido às suas 
baixas toxicidades e biodegradabilidade. Por outro lado, normalmente apresentam 
eficiências de transfecção mais baixas que os polímeros sintéticos. 
 Tendo em conta o enorme potencial que reside na aplicação de polímeros para 
entrega de DNA no interior das células, a síntese de polímeros é por isso de uma fulcral 
importância. Um dos processos mais usados na síntese de polímeros é a polimerização 
radicalar, sendo que a polimerização via RAFT sobressai de entre as demais técnicas 
devido à sua versatilidade em termos de condições de reacção e controlo sobre os 
pesos moleculares dos polímeros sintetizados. Outra característica digna de relevo é a 
baixa polidispersidade de pesos moleculares de polímeros formados por intermédio de 
polimerização via RAFT. 
 O objectivo deste trabalho foi avaliar se o PDMAEMA é um bom candidato para 
ser usado em terapia génica na retina. Para tal, PDMAEMA foi sintetizado por RAFT, 
com uma previsão inicial de peso molecular de 200 kDa. Posteriormente, o polímero 
resultante foi avaliado em termos de propriedades físico-químicas e biológicas. 
 A estrutura do polímero foi confirmada por intermédio de espectroscopias de 
H1 NMR e FTIR, pelo que a síntese, a nível químico, foi um sucesso. De modo a se 
avaliar a massa molecular do polímero, procedeu-se a uma GPC. Por intermédio desta 
técnica, verificou-se que o polímero sintetizado apresentava uma massa molecular 
média de 354 kDa, valor este superior ao esperado. Subsequente caracterização do 
polímero envolveu a execução de uma titulação potenciométrica, sendo que se 
verificou que o PDMAEMA tem um pKa de cerca de 7, muito próximo do pH fisiológico. 
O valor obtido revela que este polímero é potencialmente capaz de manter material 
genético encapsulado a valores de pH inferiores a 7 (como por exemplo no interior de 
um endossoma cujo pH ronda os 5) e, por outro lado, libertar o mesmo a um pH igual 
ou superior ao fisiológico. 
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 O PDMAEMA foi avaliado em termos de toxicidade por intermédio de um 
ensaio de contacto directo entre células e polímero. A toxicidade do material foi então 
avaliada nas linhas celulares HEK293, ARPE-19 e D407, sendo que as duas últimas são 
derivadas de células RPE, constituindo um modelo in vitro de células da retina. As 
viabilidades celulares foram avaliadas por intermédio do ensaio de MTT. Os resultados 
deste ensaio revelaram que a toxicidade do polímero é não só proporcional à sua 
concentração mas também ao tempo de duração do ensaio de incubação. Verificou-se 
também que a toxicidade do PDMAEMA é substancialmente mais acentuada nas linhas 
celulares RPE relativamente à HEK293. Não obstante este resultado, a concentração do 
material a usar num ensaio in vivo torna estes valores negligenciáveis. 
 Por intermédio de electroforese em gel de agarose, verificou-se que poliplexos 
de PDMAEMA/pDNA nas razões N/P de 5, 10 e 20 encapsularam e protegeram o DNA 
de degradação por parte de DNases. Um ensaio de libertação efectuado em poliplexos 
na razão N/P de 10 revelou que estes começam a libertar o material genético após 72 
h, a pH fisiológico. 
Poliplexos de PDMAEMA/pDNA a várias razões N/P (5, 10, 20), foram 
caracterizados em termos de tamanho e magnitude de carga de superfície por 
intermédio de medições de DLS e potencial zeta, respectivamente. Estas medições 
revelaram poliplexos com tamanho médio de 213 nm e índices de polidispersidade 
aceitáveis. O tamanho das partículas verificou-se ser inversamente proporcional à 
razão N/P. No que respeita aos potenciais zeta, a magnitude de carga média na 
superfície dos poliplexos foi de 18 mV. Os potenciais zeta obtidos foram não só 
positivos em todos os casos mas também directamente proporcionais à razão N/P, o 
que nos indica que poliplexos de PDMAEMA/pDNA interagem electrostaticamente 
com as cargas negativas à superfície das membranas biológicas, potencialmente 
facilitando a sua internalização. 
 A eficiência de transfecção de poliplexos nas razões N/P de 5, 10 e 20 foram 
avaliadas pela expressão do gene repórter GFP nas três linhas celulares previamente 
estudadas para avaliação de toxicidade. A avaliação do número de células GFP-
positivas foi efectuada por intermédio de microscopia de fluorescência. Verificou-se 
ix 
 
que todas as linhas celulares foram eficientemente transfectadas pelos poliplexos, 
pese embora a eficiência de transfecção ter sido inferior nas linhas celulares RPE. 
Ensaios preliminares para a avaliação da eficiência de transfecção em células ARPE-19, 
por intermédio de citometria de fluxo, aparentemente não indicaram a real eficiência 
de transfecção deste polímero. 
 Tomando em linha de conta os resultados como um todo, é seguro afirmar que 
o PDMAEMA é um candidato viável para terapia génica na retina. 
 
Palavras-chave: Terapia génica, vectores de entrega, RAFT, PDMAEMA, RPE. 
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I – Introduction 
 
 In the past several years, gene therapy has gained remarkable attention due to 
its potential as therapeutics for a vast array of genetic disorders like severe combined 
immunodeficiency, cystic fibrosis, Parkinson’s disease and as an alternative to 
chemotherapy employed in cancer treatment [1, 2]. DNA-based therapeutics comprise 
the use of plasmids, oligonucleotides, ribozymes, DNAzymes and small interfering 
RNAs (siRNA) as means to modulate gene expression and thus generate a therapeutic 
effect [2]. Despite the enormous potential for DNA-based therapeutics, several 
barriers hinder genetic material delivery to its site of action resulting in a poor 
therapeutic effect [3]. 
Primarily, gene therapy focused on mechanical and electrical approaches to 
insert the DNA into the cells, resorting to strategies like microinjection [4], particle 
bombardment, pressure-based [5] and electroporation [6]. Microinjection is an 
extremely efficient technique because one cell at a time is submitted to DNA transfer 
but becomes impractical because of the time this technique takes to perform. Particle 
bombardment equipment such as the gene gun can be employed in the ballistic 
transfer of DNA-gold nanoparticles; however, this approach requires direct exposure of 
the target tissue, which restricts its use to the dermis, muscle or mucosal tissues unless 
a surgical intervention can expose another normally deep tissue. Electroporation is a 
technique based on high-voltage electric current to ease DNA transfer, resulting in high 
cell mortality rendering it useless for clinical use. The use of the aforementioned 
techniques results in significant transfection efficiencies but they are very difficult to 
standardize in a clinical scenario and are regarded as laborious, time consuming, 
impractical and invasive [5]. 
In gene therapy, it is critical to overcome the barriers presented by the cell, in 
order for its therapeutic potential to be achieved so vector assisted delivery of the 
genetic material is fundamental [1, 2]. Delivery of genetic material can generally be 
described as depicted in figure 1, and four events dictate its effectiveness: genetic 
material complexation by the delivery vector, cellular internalization, endosomal 
escape and nuclear translocation of the genetic material. 
2 
 
 
 
Figure 1 – Schematics of the delivery of a DNA-based therapeutic by a viral or nonviral DNA delivery 
vector. (1) – complexation of genetic material by the delivery vector. (2) – DNA-based therapeutic-
delivery vector complex interacts with cell membrane. (3) – internalization of the complex via receptor 
or nonreceptor endocytotic pathways. (4) – endosomal escape. (5) – release in the cell cytoplasm of the 
complex or nude genetic material. (6) – dissociation of the genetic material from the vector. (7) – 
nuclear translocation of the genetic material (Scheme adapted from [2]). 
 
 The first thing to consider in vector-assisted delivery is the complexation of the 
DNA with the vector [figure 1, (1)] to a size that enables internalization by the cells. 
When using polymer-based vectors, the charge density and ionicity of the polymer 
become of major relevance. The optimal size of a polymer/DNA complex (polyplex) is 
subject to debate although smaller sizes (bellow 150 nm) are favored. Moreover, 
minimizing aggregation of the polyplexes is an important concern to the whole DNA 
delivery because aggregates can impair internalization of the complexes in the cell [7]. 
 In gene delivery, the first obstacle presented by the cell is the plasma 
membrane [figure 1, (2) and (3)]. It is well-established that native plasma membranes 
are characterized by an asymmetric distribution of charged (anionic) lipids across the 
membrane, resulting in an overall negative charge across membrane surface [8] which 
prevents by electrostatic repulsion the entry of naked DNA into the cell. Two routes 
are possible in the transfection of nonviral DNA complexes: nontargeting cationic 
complexes associate with the cell membrane through electrostatic interaction with 
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proteoglycans present in the plasma membrane surface [9]; vector systems with 
attached receptor ligands (ex.: folate, mannose or transferrin) that bind to the 
receptor on the cell surface, promoting the internalization of the DNA-vector complex 
by clathrin-dependent endocytosis [10]. 
 After cell internalization, most polyplexes are sequestered in the endosomal 
compartment [figure 1, (4)] which eventually fuses with lysosomes. These endosomal 
compartments have a lower pH (around 5.0) than the cytosol or intracellular space 
(around 7.4) and potent enzymes that may either degrade or swell the cationic 
polymer resulting in the release and degradation of DNA [11, 12]. Therefore, polyplex 
or DNA escape to the cytoplasm [figure 1, (5) and (6)] is critical to the whole gene 
delivery process and an efficient destabilization of the endosomes by endosomolytic 
compounds (ex.: chloroquine, lipids and peptides) [13-15] as well as polymers that 
possess this endosomal disruptive property [16, 17] would yield better gene delivery 
efficiency. Alternatively, it has been hypothesized that polymers with excessive amine 
groups lower the pH of the endosomes leading to endosomal swelling and collapse 
[18]. This phenomenon known as the “proton sponge” effect was first postulated to 
explain the disruptive properties of polyethylenimine (PEI) towards endosomes. 
According to this hypothesis, polyplexes trapped into the endosomes absorb the 
protons that are pumped into the organelle and the protonation of the amines present 
in the polymer structure leads to its swelling. This build-up of a positive charge 
gradient is neutralized by an influx of Cl- ions resulting in an increase in osmotic 
pressure that destabilizes and ruptures the endosomes, leading to the release of the 
endosomal content in the cytoplasm [18, 19]. 
 After reaching the cytoplasm, vector/DNA complexes can diffuse to the nuclear 
membrane [figure 1, (7)]. Molecular motors can transport the complexes to the 
nuclear membrane, although it remains unknown which properties should the delivery 
vector have to enhance this process. Furthermore, polyplex dissociation in the 
cytoplasm leads to DNA degradation which is problematic because translocation of 
unpacked DNA to the nucleus is probably through diffusion which is a slower process 
than its cytoplasmic degradation, resulting in an overall inefficient nuclear transport 
[20]. The pathway of the transport of vector/DNA complexes to the nucleus remains 
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unclear and only a few synthetic polymers, such as PEI, protect DNA against 
degradation in the cytoplasm [7]. 
Dividing cells present higher transfectability than non-mitotic cells, suggesting 
that the nuclear envelope disassembly during mitosis may ease the passage of 
exogenous DNA to the nucleus [21]. Also, in transfection studies of DNA complexed by 
a cationic vector these complexes yielded higher gene expression in comparison to 
free pDNA (plasmid DNA), indicating that vectors that are positively charged may exert 
a nuclear-localizating effect [22]. Nevertheless, intact polyplexes can be detected in 
the nucleus of even non-dividing cells and it would be of major importance to identify 
which property should these polyplexes have in order to increase translocation[4]. 
 As previously stated, delivery systems play a major role in gene therapy, 
enabling this approach to fulfill its therapeutic potential. In this sense, the ideal 
properties of a delivery vector should include high transfection efficiency with high 
target cell specificity, biodegradability, low toxicity and immunogenicity, and 
constitute a stable pharmaceutical formulation. An ideal delivery system should also 
be simple to formulate and permit modifications for customized DNA delivery, release 
and expression. 
Nowadays, there are two main DNA delivery systems, classified based on their 
origin: viral and nonviral delivery systems [2].  
 Millions of years of evolution made viruses powerful infective agents, capable 
of transferring genetic material into host cells with extreme ease. This property is very 
appealing to gene therapy applications. In general, a viral approach is characterized by 
inserting a transgene of therapeutic interest in the viral genome and use the virus 
innate mechanism of infection to introduce the expression cassette inside cells, 
allowing the gene to enter the nucleus and eventually by leading to its expression [23]. 
Several viruses can be used as delivery systems such as retrovirus [24], parvoviruses, 
adenoviruses, lentiviruses [25], adeno-associated viruses [26] and the herpex simplex 
virus [27]. The main advantage of using viruses as delivery vectors is their extremely 
high transfection efficiency: for instance, retroviral vectors can transfect between 45 
and 95% of populations of primary endothelial and smooth muscle cells, which are 
usually rather difficult to transfect [28]. Due to their efficiency, viral systems have had 
a remarkable impact in the treatment of diseases like muscular dystrophy [29], AIDS 
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[30] and cancer [31]. However, there are several concerns over these viral systems to 
deliver therapeutic DNA in humans. The main issue is the potential for generating 
strong immune responses against the viral proteinaceus capsid. There are numerous 
reports of this phenomenon in studies with animal models [32, 33]. Another concern is 
based on the potential integration of the therapeutic genes into the host genome, 
taking place randomly, potentially generating insertional mutagenesis that may inhibit 
or activate the expression of normal cellular genes or oncogenes, respectively. The 
viral envelope has a finite loading capacity, restricting the size of the plasmid it can 
incorporate. For instance, first generation adeno-associated viruses displayed a very 
limited capacity (around 4,7 kb) severely limiting their applicability [34]. Additionally, 
adenoviruses have been shown to not be stable after storage [35] and are known to 
generate inflammatory responses in tissues [36]. Finally, retroviral vectors are difficult 
to produce on a large scale [24]. The viral approach in gene therapy has been severely 
hampered by these limitations and scientists have been increasingly driving their 
attention to the nonviral systems. 
 The nonviral delivery systems can circumvent some of the issues regarding viral 
vector namely in terms of immune response (low or inexistent in most cases), ease of 
formulation and assembly. Based on the nature of the material used, nonviral vectors 
can be grouped in two categories: liposomal and polymeric delivery systems [37]. 
 Liposomes are a very attractive tool in gene therapy and can be used to deliver 
DNA-based therapeutics by entrapping them inside the aqueous core or complexing 
them to the phospholipid lamellae. Liposomal delivery systems are often 
nonimunogenic and since their composition can be manipulated, liposomes can be 
engineered in a way to display defined properties like size, surface charge, composition 
and morphology. Some liposomes with positive surface charge can interact 
electrostatically with the negatively charged DNA, complexing it in lipoplexes. These 
systems can also shield DNA against nucleases therefore improving its biological 
stability [38]. There are numerous liposomal delivery systems (figure 2) such as: 
cationic, anionic, pH-sensitive, immunoliposomes and stealth liposomes. 
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Figure 2 – Chemical structures of some commercially available liposome reagents used for gene delivery 
(Image adapted from [1]). 
 
Regarding cationic liposomes, the cationic lipids present in a liposomal 
formulation serve the purpose of complexation and condensation of DNA during 
formation of the lipoplex while zwitterionic lipids aid in membrane perturbation and 
fusion. This strategy has had an acceptable success in gene transfer [39] although 
cytotoxicity of cationic lipids has been reported not only in vitro [40] but also in vivo 
[41]. Moreover, transfection efficiencies of cationic liposomal vectors are very low in 
comparison to viral vectors, which are attributed to the heterogeneity and instability 
of these lipoplexes [42]. The potential of anionic liposomal delivery systems has been 
investigated as an alternative to cationic liposomes, with successful delivery of 
oligonucleotides to hippocampal neurons reported. On the other hand, several 
problems arise from the use of anionic liposomes such as inefficient entrapment of 
DNA resulting from electrostatic repulsion between the lipids and DNA [43] and poor 
data regarding toxicity of these materials [42]. Liposomal delivery systems which are 
pH-sensitive are potentially very useful in gene therapy due to the fact that these lipids 
are arranged in a bilayer structure at pH 7 but upon endosomal compartmentalization 
they become protonated and collapse, leading to disruption and destabilization of the 
endosome and rapid release of DNA into the cytoplasm [44]. Immunoliposomes are 
gene delivery systems that excel in cell targeting by functionalization of antibodies to 
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lipid bilayers to facilitate receptor-mediated endocytosis of lipoplexes [45]. In order to 
avoid immune responses, some liposomal formulation include polyethylene glycol 
(PEG)-conjugated lipids – stealth liposomes, resulting in a prolonged systemic 
circulation of these liposomes [46]. 
 Polymeric delivery systems often compromise the use of cationic polymers 
because they can complex anionic DNA molecules generating polyplexes used to 
deliver DNA into cells [47]. The mechanism by which polyplexes are formed relies on 
the electrostatic interaction between the positively charged polymer and the anionic 
phosphate groups in the backbone of DNA molecules, therefore forming a complex 
[48]. This approach often includes the use of dendrimers [37], PEI [49], poly(L-lysine) 
(PLL) [50] and chitosan [51]. The most important advantages of polymeric delivery 
systems are the versatility of physicochemical properties and ease of manipulation 
intrinsic to the polymers; moreover, scale-up procedures are feasible with a low cost. 
Although polymers offer some very interesting advantages, they have issues such as 
low transfection efficiencies, problems in the control of molecular weight distribution 
and high dispersity of polyplexes [37].   
 
 
Figure 3 – Chemical structure of PAMAM dendrimers (Image adapted from [4]). 
 
 Dendrimers such as polyamidoamine (PAMAM) (figure 3) possessing a 3-
dimensional spherical structure, have an advantage at synthesis control level in terms 
of degree and generation of branching, leading to the formation of polymer particles 
with very low polydispersities and consequently to reproducible gene delivery and 
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clinically reliable formulation. Amino acid residues in the structure of PAMAM 
dendrimers can interact with DNA and promote endosomal release [37]. 
 
 
Figure 4 – Chemical structure of branched PEI (Image adapted from [4]). 
 
 A polymer worth of notice is PEI (figure 4), possessing a high cationic potential 
resulting in high transfection efficiencies but also extreme cytotoxicity owing to its 
capability of inducing apoptosis [52]. As aforementioned, the high transfection 
efficiency of PEI is attributable to its buffering capabilities or “proton sponge” effect, 
resulting in a rapid endosome escape [16]. The transfection efficiency and cytotoxicity 
of PEI is directly proportional to its molecular weight [53] so strategies have been 
developed to overcome this problem such as grafting copolymers like PEG to PEI [54]. 
 
 
Figure 5 – Chemical structure of PLL (Image adapted from [4]). 
 
 PLL (figure 5) is a biodegradable cationic polymer characterized by low 
transfection efficiencies owing to its weak buffering capabilities, resulting in a poor 
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endosomal escape [55]. Also, PLL/DNA polyplexes have a high degree of polydispersity 
[48]. Consequently, this polymer is nowadays used in gene therapy as an adjunct to 
graft copolymers and endosomolytic compounds to improve cellular uptake and 
targeting of other polymers [56]. 
 
 
Figure 6 – Chemical structure of PDMAEMA (Image adapted from [57]). 
 
 PDMAEMA (figure 6) is a water-soluble cationic polymer that is also capable of 
interacting electrostatically with DNA to generate stable polyelectrolyte complexes 
[58]. Previous studies demonstrated that PDMAEMA transfection efficiency is directly 
proportional to its molecular weight [59]. The introduction of hydrophobic monomer 
units by copolymerization of 2-(N,N’-dimethylamino)ethyl methacrilate (DMAEMA) 
with methyl methacrylate monomers (20 mol%) resulted in a polymer with low 
transfection efficiency and increased cytotoxicity; on the other hand, copolymerization 
of DMAEMA with hydrophilic N-vinyl-pyrrolidone (NVP) monomers (54 mol%) 
enhanced transfection efficiency and greatly reduced cytotoxicity, in comparison to 
PDMAEMA homopolymer, meaning that transfection efficiency and cytotoxicity should 
be balanced in order to achieve optimal transfection by manipulating the charge 
density and hydrophobicity of the cationic polymeric vector. Additionally, the tertiary 
amine groups of PDMAEMA are partially protonated at physiological pH since the 
average pKa of the amine groups is 7.5 [60], conferring buffering properties to the 
polymer in the endosomal compartment. Structural analogs with a higher pKa value 
yielded much lower transfection efficiencies than PDMAEMA because the higher 
degree of protonation of the amines resulted in lower buffering capabilities and 
increased DNA affinity, ultimately leading to poor endosomal escape and DNA 
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dissociation from the polyplex and overall decrease in transfection efficiency [61]. The 
size and zeta potential of PDMAEMA/DNA polyplexes were shown not only to be 
dependent of the N/P ratio but also as important factors in determining transfection 
efficiency [62]. Highly charged (30 mV) polyplexes, around 200 nm in size, yielded the 
highest transfection efficiency in vitro, when evaluated in COS-7, OVCAR-3 and B16 cell 
lines [57]. PDMAEMA achieved a transfection efficiency around 10% in vitro and 1-2% 
in vivo when intraperitoneally grown OVCAR-3 cells were transfected ex vivo [63]. 
Despite this discrepancy between in vitro and in vivo performance in terms of 
transfection efficiency and cytotoxicity issues, PDMAEMA still has enormous 
applicability as a gene therapy tool. 
 
 
Figure 7 – Chemical structure of chitosan (Image adapted from [7]). 
 
 Besides synthetic polymers, natural polymers are also used in gene delivery and 
one of the most popular is undoubtedly chitosan (figure 7). This polymer is obtained by 
deacetylation of the chitin that composes the exoskeleton of arthropods. It is a 
biodegradable polysaccharide consisting of repeating D-glucosamine and N-acetil-D-
glucosamine units, linked via (1-4) glycosidic bonds [64] and can be characterized by 
properties such as molecular weight, degree of deacetylation, viscosity and crystallinity 
[65]. Due to its low toxicity, chitosan is used in gene delivery as an alternative to PEI 
despite yielding substantially lower transfection efficiencies than the latter [66]. 
 Previously, it was demonstrated that polymers as nonviral delivery vectors are 
extremely appealing to gene therapy, so polymer synthesis is fundamental in the 
development of new polymers to be applied in this approach. One of the most used 
processes for polymer synthesis is radical polymerization [67] and considerable effort 
has been done in the past years to develop synthesis techniques more effective than 
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the free-radical polymerization [68]. The living polymerization processes have many 
advantages over free-radical polymerization including the ability to control molecular 
weight, polydispersity and possibility of preparing block copolymers or polymers of 
complex structure. Taking this into account, it would be desirable to have 
polymerization techniques which combined the benefits of living polymerization with 
the versatility and convenience of free-radical polymerization. However, these 
techniques present some disadvantages such as being applicable only to a narrow 
range of monomers, require expensive reagents or high temperatures to perform. The 
RAFT polymerization emerges from other living free-radical polymerization techniques 
because it performs for a wider range of monomers and reaction conditions, yielding 
polymers with controlled molecular weight and narrow polydispersities [69].  
 
 
Figure 8 – Proposed RAFT mechanism (Image adapted from [70]). 
 
 The RAFT mechanism involves polymerization of a substituted monomer in the 
presence of a chain transfer agent (CTA) and the latter [figure 8, (1)] normally has a 
thiocarbonylthio group (S=C-S) with substituents Z and R in its structure which severely 
impact the kinetics of the reaction as well as the degree of structural control. The 
reaction can be initiated by thermal, redox or γ-irradiation methods. The reaction 
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begins by addition of initiator-derived radicals to the monomer [figure 8, (a)], resulting 
in the formation of almost only CTA-derived chains (Pm•) [figure 8, (b) and (c)] 
originated from the fragmentation product (R•) of the intermediate species (2). To 
favor this reaction path, in a RAFT polymerization the concentration of initiator is kept 
low comparatively to the CTA and the reactivity of the latter should be higher than that 
of the monomer. The reversible fragmentation of the intermediate species (2) and 
consumption of CTA (1) to generate the reinitiating fragment (R•) is referred as “pre-
equilibrium” [figure 8, (c)]. The “main equilibrium” [figure 8, (d)] is achieved when 
active radical chain ends react with the monomer or reversibly to dormant chains (or 
macro-CTAs). The rapid establishment of the “pre-equilibrium”, efficient reinitiation by 
the fragmentation product (R•) and attainment of the “main equilibrium” in which the 
population of dormant chains and/or intermediate radicals (5) is remarkably higher 
than that of propagating chains (Pn• and Pm•), appears to be the cause of obtaining 
narrow molecular weight distributions in a RAFT polymerization. The pseudo-first-
order kinetics and the linear evolution of molecular weight over time, attest to a 
significant elimination of chain termination events [figure 8, (e)] [70]. 
 The aim of this work was to evaluate if PDMAEMA would be suitable as a 
delivery vector for gene therapy in the retina. To this purpose, we synthesized 
PDMAEMA with a predicted Mw of 200 kDa and characterized its physicochemical 
properties by H1 NMR and FTIR spectroscopies, GPC and potentiometric titration. The 
cytotoxicity of the resulting polymer was evaluated by MTT assays performed not only 
in HEK293 cells but also in RPE cell lines ARPE-19 and D407. PDMAEMA/pDNA 
polyplexes at various N/P ratios were studied in order to determine their capabilities 
to encapsulate and protect DNA from DNase degradation as well as to establish their 
release profiles in vitro. Additionally, these polyplexes were characterized in terms of 
size and magnitude of surface charge by DLS and zeta potential measurements, 
respectively. Finally, the transfection efficiency of these polyplexes was evaluated in 
vitro by fluorescence microscopy and flow citometry techniques. 
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II – Materials and methods 
 
2.1 – Synthesis of PDMAEMA 
 
 The polymer was synthesized by RAFT polymerization. Prior to the synthesis, 
DMAEMA was passed through a neutral alumina column to remove free radical 
inhibitor. DMAEMA (1 mL, 5,93x10-3 mol), O-ethyl phthalimidyl methyl xanthate 
(0,0011 g, 3,95x10-6 mol) and 2,2'-azobisisobutyronitrile (AIBN) (1 mol % monomer, 
0,0097 g) were added to tetrahydrofuran (THF) (approximately 5 mL) in a Shleck flask. 
The reaction mixture was submitted to three freeze-pump-thaw cycles. The flask was 
then submerged in an oil bath preheated to 60 oC and the polymerization was allowed 
to proceed for 24 h under magnetic stirring. The resulting polymer was precipitated by 
pouring the mixture into hexane and centrifuged at 10 000 rpm for 10 min; afterwards 
the supernatant was discarded and the same process was repeated with the pellet two 
more times. The polymer was then dried under vacuum at 40 oC for 72 h. The neutral 
PDMAEMA product obtained was added to water and drops of 12 M HCl were added 
under stirring until the polymer completely dissolved, due to its conversion into the 
hydrochloride salt. The PDMAEMA•HCl polyelectrolyte was then precipitated in 
acetone, the mixture was cooled at -20 oC for 10 min and centrifuged at 10 000 rpm for 
10 min. The white powder constituting the pellet was recovered and dried under 
vacuum at 60 oC overnight.  
 
2.2 – 1H NMR spectroscopy 
 
 The 1H NMR analysis was performed in a Bruker ARX 400 (400 MHz). 1H NMR 
(D2O)   1,238-1,106 (d, CH3-C-C=O), 2,119 (s, CH2-C-C=O), 3,089 (s, (CH3)2-N-C-C-O), 
3,667 (s, CH2-C-O), 4,490 (s, CH2-O-C=O). 
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2.3 – Gel permeation chromatography 
 
Triple detection GPC (SEC3) analysis was performed in a modular system 
constituted by a degasser, HPLC pump (K-1001) and RI detector (K-2300) are from 
Knauer; viscometer and RALLS are from Viscotek (Trisec Dual Detector Model 270), 
using two PL aquagel-OH mixed 8 m 300 x 7.5 mm columns and using two PL aquagel-
OH mixed columns. Eluent was 0,5 M NaNO3 in pH 2 phosphate buffer (containing 
0.1% sodium azide) at 1mL/min. The sample was dissolved at 10 mg/mL in 10-2 M HCl 
solution. 
 
2.4 – FTIR spectroscopy 
 
The PDMAEMA FTIR spectrum was recorded in a KBr pellet within the range 
4000-600 cm-1 in a Bruker, Tensor 27 spectrophotometer. IR (KBr): 1730 ( (C=O)) and 
1148 ( (C-N)). 
 
2.5 – Potentiometric titration 
 
The polymer solution was prepared in 10 mL of distilled water at a fixed total 
titratable amine group concentration of 10 mM. A pH measurement electrode (Orion 
9157BN) connected to an Orion pH meter (Thermo Orion 4 Star pH-ISE Benchtop) 
(calibrated using two standard pH buffers (pH 4.00 and 10.00)) was then immersed 
into the solution and the system was allowed to reach an equilibrium. The pH of the 
solution was preadjusted to approximately 2.00 by addition of 2 M HCl. Afterwards, 
the titrant (0.08 M NaOH) was added dropwise to the polymer solution by using a 
micropipette (with a drop size of 20-40 μL) under constant stirring and the stabilized 
pH value was recorded after each dropwise addition of the titrant. 
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2.6 – Cell culture 
 
In this work three different cell lines were used for in vitro assays: HEK293, 
ARPE-19 and D407. HEK293 is a cell line originally derived from human embryonic 
kidney cells [71] which grow very fast and are easily transfected. Due to its properties, 
HEK293 cells were used as a control in transfection assays. On the other hand, ARPE-19 
and D407 are human RPE cell lines that retained phagocytic capacity making them 
excellent in vitro models for RPE cells [72, 73]. ARPE-19 cells were originally derived 
from the healthy eye of a 19 year-old male and express RPE-specific markers [73]. 
D407 cells were originally derived from the eye of a 12 year-old male and present 
trisomy [72]. Despite expressing the same RPE-specific markers as ARPE-19 cells [72], 
D407 cells are unable to produce pigments as the former [73]. 
The cell cultures were incubated at 37 oC in a humid atmosphere of 5% CO2. 
The HEK293 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 
5% fetal bovine serum (FBS), 1% L-glutamine and 1% penicillin/streptomycin; ARPE-19 
cells were cultured in DMEM/Ham’s F-12 mix with 5% FBS, 1% L-glutamine and 1% 
penicillin/streptomycin; D407 were cultured in DMEM with 10% FBS, 1% L-glutamine 
and 1% penicillin/streptomycin. 
 
2.7 – Cell viability assay 
 
 As previously stated, it is desirable for a delivery vector to display the least 
cytotoxicity possible. Bearing this in mind, a direct contact assay between cells and 
polymer was performed for the HEK293, ARPE-19 and D407 cell lines to determine cell 
viabilities after three time points (24, 48 and 72 h). Cell viability was determined using 
the 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) assay. HEK293, 
ARPE-19 and D407 cells were plated at a concentration of approximately 5x104 
cells/well on 12-well plates 24 h prior to the experiment. Prior to each assay, the 
medium was renewed with 1,5 mL/well (with the exception of D407 cells in which 1 
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mL/well was used). PDMAEMA solution (1 mg/mL in 1x PBS) was added dropwise to 
the wells to obtain final masses of polymer as follows: 10, 15, 20 and 30 µg. A negative 
and a positive control of cell viability were performed where the cells were treated 
with medium containing a latex extract which is toxic for cells or fresh medium, 
respectively. All experiments were performed in duplicate. The plates were then 
incubated for 24, 48 or 72 h at 37 oC, 5% CO2. After each time point, 100 µL of MTT 
solution (5 mg/mL) were added to each well. After 4 h of incubation at 37 oC, 5% CO2, 
the medium was removed from each well and 500 µL of a 0,04 M HCl in isopropanol 
solution were used to dissolve the formazan product. For each well in the 12-well 
plate, 100 µL of the crystal solution were transferred to three different wells in a 96-
well plate. Absorbances at 570 and 630 nm were measured using a TECAN Infinite 
M200 microplate reader. 
 
2.8 – Dynamic light scattering and zeta potential measurements of 
PDMAEMA/pDNA polyplexes 
 
2.8.1 – Polyplex preparation 
 
 To prepare polyplexes for the DLS and zeta potential measurements, 0,5 µg of a 
plasmid encoding the green fluorescent protein (GFP) (pAAV.2.1.GFP) in 
Tris/Borate/EDTA (TBE) were added to 1 x phosphate buffer saline (PBS). Afterwards, a 
certain volume of a PDMAEMA solution (1 mg/mL in 1x PBS) was also added, the 
mixture was mildly vortexed for 10 s and allowed to incubate at room temperature for 
30 min for the DNA/PDMAEMA complex to be established. 
The appropriate volumes of the polymer solution to be added were in 
agreement to the various N/P ratios tested (5, 10 and 20) and were calculated 
according to equation 1. 
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Equation 1 –  
 
 
 
      
      
 
 Where N/P stands for the ratio of nitrogen atoms present in the polymer to 
phosphorus atoms in the DNA molecule, mp and mD are the mass of polymer and DNA 
respectively, Mo,p and Mo,D are the repeat unit molecular weight of polymer and 
average repeat unit molecular weight of DNA respectively. The equation assumes that 
there is only one ionizable amine group present in the polymer’s monomer unit. 
 The amount of PBS used in each ratio is that sufficient to obtain a final volume 
of 100 µL for each ratio.  
 
2.8.2 – DLS and zeta potential measurements 
 
To characterize PDMAEMA/pDNA polyplexes at various N/P ratios (5, 10 and 20) 
in terms of diameter and magnitude of surface electrical charge, DLS and zeta potential 
measurements were performed, respectively. For the DLS measurements, to a 
disposable plastic cuvette with 1 mL of milli-Q water, were added 20 µL of polyplex 
solution and thoroughly mixed prior to measurement. For the zeta potential 
measurements, 20 µL of polyplex solution were added to 1 mL of milli-Q water, 
thoroughly mixed and placed in a disposable capillary cell prior to measurement. The 
DLS and zeta potential measurements were performed on a Malvern Zeta Sizer Nano 
Series Nano-ZS instrument. All experiments were performed in triplicates at a 
temperature of 25 oC. 
 
2.9 – DNA gel shift assay 
 
To determine if PDMAEMA is able to completely bind and load DNA in 
polyplexes, a DNA gel shift assay was performed. In this technique, migration in the gel 
is retarded for polyplex samples in which the polymer is efficiently binding to the DNA, 
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in contrast to naked DNA which migrates on a gel when subjected to voltage. 
Polyplexes were prepared as described in section 2.8.1 with the scale up of the 
experiment where 2 µg of plasmid DNA were complexed with the polymer in a final 
volume of 50 µL for each N/P ratio (5, 10 and 20). Prior to loading the samples in an 
agarose gel, 7 µL of loading buffer were added to each sample. To prepare the gel, 
agarose (Invitrogen) was added to 1x TAE buffer, the mixture was heated in a 
microwave till the agarose completely dissolved and 1µL of ethidium bromide (10 
mg/mL, Sigma) was added to produce 1 wt % agarose gel. The gel was subjected to a 
voltage of 60 V for about 1 h in 1x TAE buffer. The gel was imaged using a UV 
transilluminator (AlphaImager) equipped with a digital camera. 
 
2.10 – DNase I protection assay  
 
An import characteristic a gene delivery vector should present is the ability to 
protect DNA against degradation which promotes the delivery of the genetic material 
to the nucleus. PDMAEMA/pDNA polyplexes were incubated with DNase I to evaluate 
their capability to protect the genetic material from enzymatic degradation.  
Polyplexes were prepared as described in section 2.8.1 with 0,5 µg of plasmid DNA 
complexed with the polymer in a final volume of 20 µL for each N/P ratio (1; 2,5; 5 and 
10). An amplification grade DNase I kit (Sigma) was used in this experiment to digest 
DNA in the polyplex samples. To digest DNA in the polyplex samples, 1 µL of 10x 
reaction buffer (200 mM Tris-HCl, pH 8.3, 20 mM MgCl2) and 1 µL of amplification 
grade DNase I (1 unit/μl in 50% glycerol, 10 mM Tris-HCl, pH 7.5, 10 mM CaCl2, 10 mM 
MgCl2) were mixed with the polyplexes. The mix was incubated at room temperature 
for 30 min after which 1 µL of 50 mM ethylenediamine tetraacetic acid (EDTA) was 
added to stop the reaction. To completely inactivate DNase I, the samples were 
immersed in a water bath preheated to 70 oC for 15 min. Afterwards, the samples 
were cooled on ice and 5 µL of loading buffer were added. A positive control of DNA 
degradation was performed in which 0,5 µg of pDNA in 1x PBS (20 µL) were subjected 
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to the same procedure as the PDMAEMA/pDNA polyplexes. Finally, the samples were 
run in an agarose gel subjected to the same procedure as described in section 2.9. 
 
2.11 – DNA release assay from PDMAEMA/pDNA polyplexes 
 
To determine the time point at which the release of the genetic material occurs, 
PDMAEMA/pDNA polyplexes at N/P ratio of 10 were dialyzed against 1x PBS, followed 
by a DNA gel shift assay performed on samples collected during the dialysis procedure. 
Polyplexes were prepared as described in section 2.8.1 with the scale up of the 
experiment where 2,1 µg of plasmid DNA were complexed with the polymer in a final 
volume of  500 µL for an N/P ratio of 10. The polyplex solution was injected in a dialysis 
cassette (Slide-A-Lyzer Dialysis Cassette, 10K MWCO, 0,5 mL, Pierce) and dialyzed 
under magnetic stirring against 2 L of 1x PBS. Samples of 70 µL were taken from the 
cassette each 24 h and the 1x PBS was replaced with fresh one. To detect the release 
of plasmid DNA, a DNA gel shift assay was performed as described in section 2.9. 
 
2.12 – In vitro transfection assay 
 
In order to quantify the transfection efficiencies of PDMAEMA/pDNA 
polyplexes at various N/P ratios (5, 10 and 20), HEK293, ARPE-19 and D407 cells were 
transfected with these polyplexes and expression of GFP was analyzed after 24, 48 and 
72 h of cell transfection. To detect GFP-positive cells, two techniques were performed: 
fluorescence microscopy (qualitative approach) and flow citometry (quantitative 
approach). 
For the fluorescence optical microscopy analysis, polyplexes were prepared as 
described in section 2.8.1 with the scale up of the experiment where 1 µg of plasmid 
DNA was complexed with the polymer in a final volume of 200 µL for each N/P ratio (5, 
10 and 20). A positive control of transfection was performed using FuGENE HD 
(Promega) according to the manufacturer’s instructions. Also, a negative control of 
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transfection was performed in which cells were subjected to the same procedures as 
the others present in other samples with the exception of the addition of transfection 
solution. HEK-293, ARPE-19 and D407 cells were plated at a concentration of 
approximately 5x104 cells/well on 12-well plates 24 h prior to the experiment. Prior to 
each assay, the medium was aspirated from each well and the cells were supplied with 
fresh medium without FBS. To each treatment well, 100 µL of polyplex solution or 
FuGENE lipoplex solution were added dropwise. After 2h incubation with the particles, 
FBS was supplied to the cells according to the amount each cell line required. All 
treatments were performed in duplicate. After each time point, the plates were 
visualized by fluorescence microscopy consisting of a Leica DM IL inverted microscope 
equipped to a Leica epifluorescence system and Leica DC500 digital camera. 
In regard to the flow citometry analysis, the same transfection procedure as 
previously described was adopted but in this assay only ARPE-19 cells were studied. 
Also, 6-well plates were used and approximately 1x105 cells/well were plated in this 
assay. Moreover, the polyplex and lipoplex formulations comprised the complexation 
of 2 µg of plasmid DNA. After 72 h of transfection, the cells were collected and 
resuspended in 3 mL of 1x PBS. The cells were washed again, resuspended in 1 mL of 
1x PBS and transferred to RIA tubes. Fluorescence activated cell sorting (FACS) analysis 
was performed using a BD FACSCalibur. Appropriate gating procedures were used to 
ensure only live cells were analyzed. 
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III – Results 
 
3.1 – 1H NMR spectroscopy 
 
 The spectrum bellow (figure 9) was obtained by 1H NMR spectroscopy (400 
MHz, D2O) analysis of PDMAEMA. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – 
1
H NMR spectrum (400 MHz, D2O) of PDMAEMA. 
 
Based on the 1H NMR spectrum (400 MHz, D2O) of the polymer (figure 9), the 
peaks at 1,106 and 1,238 ppm correspond to the CH3-C protons [figure 19, (a)] 
whereas the signal at 2,119 ppm refers to CH2-C protons [figure 19, (b)]. Chemical 
shifts at 3,089 and 3,667 ppm correspond to protons in (CH3)2-N [figure 19, (e)] and 
CH2-N [figure 19, (d)], respectively. Finally, the peak at 4,490 ppm accounts for CH2-O 
a b 
e 
d c 
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protons [figure 19, (c)]. The 1H NMR spectrum in figure 9 corresponds to that reported 
in [59]. 
 
3.2 – Gel permeation chromatography 
 
 Figure 10 shows the three signals in the GPC chromatogram obtained for 
PDMAEMA. 
 
 
 
Figure 10 – GPC (SEC3) triple detection (concentration (RI), viscosity (DP) and light 
scattering (LS)) signals (mV) as a function of the retention volume (mL). 
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GPC analysis revealed a monomodal molecular weight distribution, with 
number-average molecular weight (Mn) of 270 100 Da and Mw of 354 000 Da. Based on 
these values, a PDI (Mw/Mn) of 1,31 was calculated for PDMAEMA. 
 
3.3 – FTIR spectroscopy 
 
 The following image represents the FTIR spectrum obtained for PDMAEMA. 
 
 
Figure 11 – FTIR spectrum of PDMAEMA recorded in a KBr pellet within the range 4000-600 cm
-1
. 
 
 In the FTIR spectrum (figure 11), we can visualize absorbing bands of 1730 and 
1148 cm-1 corresponding to the stretching frequencies of C=O and C-N groups, 
respectively. These typical bands of interest corresponding to groups present in 
PDMAEMA chemical structure were also reported in [74]. 
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3.4 – Potentiometric titration 
 
The titration curve for PDMAEMA is represented in figure 12. 
 
 
Figure 12 – Potentiometric titration curve of PDMAEMA.  
 
 Two equivalence points are visible in the potentiometric titration curve 
previously represented. The first equivalence point is around pH 4.5 and corresponds 
to the HCl which was added to the analyte solution prior to the titration to lower the 
initial pH and to guarantee that all the titrable amines in the structure of the polymer 
were initially protonated. This first equivalence point is of no real direct consequence 
in the assay, whereas the equivalence point of interest (PDMAEMA) is around pH 9.5. 
By analysis of the titration curve, PDMAEMA’s pKa was determined to be around pH 7, 
very close to physiological pH. 
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3.5 – Cell viability assay 
 
For each well in the 96-well plate, the absorbance  at 630 nm was discounted in 
the absorbance at 570 nm, as described in the following equation. 
Equation 2 –                         
Therefore, all corresponding optical densities (OD) were averaged according to 
each condition and the cell viabilities were calculated as following: 
Equation 3 –                     
           
    
     
In this calculation, it was assumed that the OD of the positive control of viability 
(C+) corresponded to 100% of cell viability. In the equation, ODcondition is the OD for 
each condition tested (negative control of cell viability (C-), 10, 15, 20 and 30 µg of 
polymer). 
 
The figure 13 summarizes the results of the MTT assays performed on HEK293 
cells after 24, 48 and 72 h incubation with various amounts (10, 15, 20 and 30 µg) of 
PDMAEMA. 
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Figure 13 – MTT assay performed on HEK293 cells treated with various amounts of PDMAEMA (10, 15, 
20 and 30 µg). Cell viability was determined after 24, 48 and 72 h of direct contact between cells and 
polymer. Two controls were performed: C+ and C-, untreated cells and cells incubated with a latex 
extract, respectively. Error bars represent the standard deviation between OD of the same treatment 
group. 
 
 Based on the figure 13, there is an inverse relationship between cell viability 
and amount of polymer used in the treatment. Moreover, increasing incubation time 
with the material also decreases cell viability although some cell viability was 
recovered after 72 h in the treatments with 10, 15 and 20 µg of polymer. Taking into 
account the polymer treatments at various amounts, cell viability ranged from around 
80% (10 µg treatment) to around 40% (30 µg treatment). 
 
The figure 14 summarizes the results of the MTT assays performed on ARPE-19 
cells after 24, 48 and 72 h incubation with various amounts (10, 15, 20 and 30 µg) of 
PDMAEMA. 
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Figure 14 – MTT assay performed on ARPE-19 cells treated with various amounts of PDMAEMA (10, 15, 
20 and 30 µg). Cell viability was determined after 24, 48 and 72 h of direct contact between cells and 
polymer. Two controls were performed: C+ and C-, untreated cells and cells incubated with a latex 
extract, respectively. Error bars represent the standard deviation between OD of the same treatment 
group. 
 
 Based on these results, the same assumptions can be made as for the HEK293 
cell line. Cytotoxicity was also directly related to polymer amount in treatments and 
incubation length. Different to HEK293 cells, no condition showed recovery of viability 
at 72 h or any other time point. In general, cell viability was markedly lower than in the 
previous assay, ranging from around 60% (10 µg treatment) to around 16% (30 µg 
treatment). The latter treatment displayed very high cytotoxicity to ARPE-19 cells. 
 
The next graphic summarizes the results of the MTT assays performed on D407 
cells after 24, 48 and 72 h incubation with various amounts (10, 15, 20 and 30 µg) of 
PDMAEMA. 
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Figure 15 – MTT assay performed on D407 cells treated with various amounts of PDMAEMA (10, 15, 20 
and 30 µg). Cell viability was determined after 24, 48 and 72 h of direct contact between cells and 
polymer. Two controls were performed: C+ and C-, untreated cells and cells incubated with a latex 
extract, respectively. Error bars represent the standard deviation between OD of the same treatment 
group. 
 
 Based on the figure 15, it is again clear a direct relationship between 
cytotoxicity and polymer amount in the treatment. As in the HEK293 assay, there was a 
recovery in cell viability along incubation time but in this assay the phenomenon was 
more noticeable, with additional recoveries after 48 h in treatments with 10 and 15 µg 
of polymer. Cell viabilities ranged from around 50% (10 µg treatment) to around 10% 
(30 µg treatment). D407 cells were treated differently in the assay where 1 mL/well of 
medium was used rather than the 1,5 mL/well in the other assays. Despite the masses 
of polymer being the same in comparison to the other assays, in this case the 
concentration of polymer was higher resulting in overall lower cell viabilities. 
Comparing all the results, there is a threshold in cytotoxicity at the 20  µg of 
polymer mark, where the cell viability becomes abruptly sensitive to polymer quantity, 
especially in the RPE (ARPE-19 and D407) cell lines in which cell viabilities closely 
resemble the ones displayed in the negative control. These results as a whole reveal 
that PDMAEMA is more toxic to RPE cell lines than to HEK293 cells. 
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3.6 – Determination of PDMAEMA/pDNA polyplexes size and zeta 
potential 
 
 DLS and zeta potential measurements were used to determine the diameter 
and the magnitude of the surface electrical charge of the polyplexes, respectively. The 
following table summarizes the results for DLS and zeta potential measurements of 
PDMAEMA/pDNA polyplexes at various N/P ratios (5, 10 and 20).  
 
Table I – Characterization of PDMAEMA/pDNA polyplexes at N/P = 5, 10 and 20 ratios. Values represent 
mean ± SD (n = 3). 
 DLS Zeta potential 
N/P ratio Z-Average (d.nm) PDI Potential (mV) 
5 266,7 ± 57,2 0,387 ± 0,124 14,4 ± 2,2 
10 202,1 ± 31,9 0,334 ± 0,037 19,6 ± 1,4 
20 171,3 ± 18,6 0,304 ± 0,008 21,4 ± 5,7 
 
 The DLS measurements show an inverse relationship between the N/P ratio or 
amount of polymer used to complex pDNA and the mean diameter (nm) of the 
corresponding polyplexes. For all the N/P ratios studied, the polyplexes exhibited an 
acceptable (below 0,4) mean PDI and mean diameters ranging from 266,7 to 171,3 nm. 
On the other hand, zeta potential measurements indicate a direct relationship 
between N/P ratio and magnitude of the surface electrical charge of polyplexes. It is 
also worth mentioning that the zeta potentials measured were positive for all the ratios 
studied. 
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3.7 – DNA gel shift assay 
 
A DNA gel shift assay (figure 16) was performed to determine the capabilities of 
PDMAEMA to bind and complex DNA at various N/P ratios (5, 10 and 20). 
 
 
Figure 16 – Electrophoretic gel shift assay of PDMAEMA/pDNA polyplexes at various N/P ratios. Lane A - 
1 kb DNA Ladder (marker); lane B - naked pDNA (0,3 µg in PBS); lane C - PDMAEMA/pDNA polyplexes at 
N/P ratio of 5; lane D - PDMAEMA/pDNA polyplexes at N/P ratio of 10; lane E - PDMAEMA/pDNA 
polyplexes at N/P ratio of 20. 
 
No retardation occurred in the control were naked pDNA was loaded and 
electrophoresed normally.  In all N/P ratios studied, PDMAEMA seemed to be able to 
fully bind and load pDNA. These assumptions can be made since pDNA migration was 
completely retarded and the particles stayed on the wells in the lanes corresponding to 
the polyplexes at various N/P ratios. 
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3.8 – DNase I protection assay 
 
The following image represents the DNA gel shift assay performed to determine 
the protection from enzymatic degradation that PDMAEMA can confer to DNA when 
the two species interact electrostatically. 
 
 
Figure 17 – Electrophoretic gel shift assay of PDMAEMA/pDNA polyplexes at various N/P ratios after 30 
min incubation with DNase I. Lane A - 1 kb DNA Ladder (marker); lane B – naked pDNA (0,5 µg in PBS), 
non-digested; lane C – naked pDNA (0,5 µg in PBS), digested; lane D – PDMAEMA/pDNA polyplexes at 
N/P ratio of 1, digested; lane E – PDMAEMA/pDNA polyplexes at N/P ratio of 2,5, digested; lane F – 
PDMAEMA/pDNA polyplexes at N/P ratio of 5, digested; lane G – PDMAEMA/pDNA polyplexes at N/P 
ratio of 10, digested. 
 
 Based on the image above, the PDMAEMA/pDNA polyplexes at N/P ratios of 1 
and 2,5 (lanes D and E, respectively) did not protect DNA from enzymatic degradation 
of DNase I because in the corresponding lanes there are visible DNA smears, resulting 
from DNA degradation. In contrast, PDMAEMA/pDNA polyplexes at N/P ratios of 5 and 
10 (lanes F and G, respectively) showed enzymatic protection, shielding DNA against 
DNase I activity since no smears are visible throughout the corresponding lanes 
although the polyplexes were not visible on the wells. Interestingly, in the positive 
32 
 
A           B           C           D           E           F 
control for DNA degradation (lane C) smears resultant from DNA degradation are also 
not visible. 
 
3.9 – DNA release assay from PDMAEMA/pDNA polyplexes 
 
The following image represents the gel shift assay performed on 
PDMAEMA/pDNA polyplexes at N/P ratio of 10 submitted to dialysis against 1x PBS to 
determine the time point at which the release of the genetic material occurs. Due to 
time constrains, it was only possible to analyze polyplexes at N/P ratio of 10 in this 
assay. 
 
 
Figure 18 – Electrophoretic gel shift assay of PDMAEMA/pDNA polyplexes at N/P ratio of 10 after 
dialysis against 1x PBS. Lane A - 1 kb DNA Ladder (marker); lane B - naked pDNA (0,3 µg in PBS); lane C - 
PDMAEMA/pDNA polyplexes (N/P = 10) after 24 h dialysis; lane D -  PDMAEMA/pDNA polyplexes (N/P = 
10) after 48 h dialysis; lane E - PDMAEMA/pDNA polyplexes (N/P = 10) after 72 h dialysis; lane F - 
PDMAEMA/pDNA polyplexes (N/P = 10) after 96 h dialysis. 
 
 As shown in the previous figure, the PDMAEMA/pDNA polyplex samples 
collected after 72 and 96 h dialysis showed release of genetic material, since in the 
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corresponding lanes there are visible bands attributable to the plasmid by comparison 
to the control lane (B) where the naked plasmid ran normally. Although the polyplexes 
are not visible on the wells of lanes C and D, no plasmid bands attributable to 
uncomplexed plasmid are visible throughout the lane; therefore, no release of genetic 
material occurred at 24 or 48 h post-dialysis. Taking all these factors into account, 
PDMAEMA/pDNA polyplexes at N/P ratio of 10 start releasing genetic material after 72 
h, at physiological pH. 
 
3.10 – In vitro transfection assay 
 
 In the fluorescence microscopy analysis, each well on the plates was visualized 
and bright field as well as fluorescence filtered photos were taken at the same spot 
(fraction of the well that describes the best of the whole well). Afterwards, the photos 
were overlapped accordingly to enable visualization of total amount of cells present as 
well as GFP-positive cells in the same picture.  
Figure 19 summarizes the results of the in vivo transfection assay on HEK293 
cells. Photos were taken 24, 48 and 72 h pos-transfection for each treatment. 
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Figure 19 – Fluorescence optical microscopy photos taken on HEK293 cells transfected with 
PDMAEMA/pDNA polyplexes at various N/P ratios (0,5 µg pDNA per 5x10
4
 cells). Each image stands for a 
different treatment at a different time point: (A) – FuGENE lipoplexes, 24 h pos-transfection. (B) – 
PDMAEMA/pDNA polyplexes at N/P ratio of 5, 24 h pos-transfection. (C) – PDMAEMA/pDNA polyplexes 
at N/P ratio of 10, 24 h pos-transfection. (D) – PDMAEMA/pDNA polyplexes at N/P ratio of 20, 24 h pos-
transfection. (E) – FuGENE lipoplexes, 48 h pos-transfection. (F) – PDMAEMA/pDNA polyplexes at N/P 
ratio of 5, 48 h pos-transfection. (G) – PDMAEMA/pDNA polyplexes at N/P ratio of 10, 48 h pos-
transfection. (H) – PDMAEMA/pDNA polyplexes at N/P ratio of 20, 48 h pos-transfection. (I) – FuGENE 
lipoplexes, 72 h pos-transfection. (J) – PDMAEMA/pDNA polyplexes at N/P ratio of 5, 72 h pos-
transfection. (K) – PDMAEMA/pDNA polyplexes at N/P ratio of 10, 72 h pos-transfection. (L) – 
PDMAEMA/pDNA polyplexes at N/P ratio of 20, 72 h pos-transfection. Magnification: 100x for all 
pictures. 
 
 During fluorescence microscopy analysis, it was observed that FuGENE yielded 
the highest transfection efficiency on this cell line, reaching the peak of transfected 
cells 24 h after incubation with the lipoplexes, with no detectable variation along time. 
In contrast, all PDMAEMA/pDNA polyplexes had a peak of transfection at the 72 h 
mark, meaning that the number of GFP-positive cells increased over time. Moreover, 
an increase in N/P ratio yielded more transfection efficiency and cells transfected with 
PDMAEMA/pDNA polyplexes at N/P ratio of 20 had a transfection efficiency 
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comparable to FuGENE; however, the wells in which cells were transfected with these 
polyplexes displayed slightly lower cell viability comparing to the other treatments. 
 
Figure 20 summarizes the results of the in vivo transfection assay performed on 
ARPE-19 cells. Photos were taken 24, 48 and 72 h pos-transfection for each treatment. 
 
 
Figure 20 – Fluorescence optical microscopy photos taken on ARPE-19 cells transfected with 
PDMAEMA/pDNA polyplexes at various N/P ratios (0,5 µg pDNA per 5x10
4
 cells). Each image stands for a 
different treatment at a different time point: (A) – FuGENE lipoplexes, 24 h pos-transfection. (B) – 
PDMAEMA/pDNA polyplexes at N/P ratio of 5, 24 h pos-transfection. (C) – PDMAEMA/pDNA polyplexes 
at N/P ratio of 10, 24 h pos-transfection. (D) – PDMAEMA/pDNA polyplexes at N/P ratio of 20, 24 h pos-
transfection. (E) – FuGENE lipoplexes, 48 h pos-transfection. (F) – PDMAEMA/pDNA polyplexes at N/P 
ratio of 5, 48 h pos-transfection. (G) – PDMAEMA/pDNA polyplexes at N/P ratio of 10, 48 h pos-
transfection. (H) – PDMAEMA/pDNA polyplexes at N/P ratio of 20, 48 h pos-transfection. (I) – FuGENE 
lipoplexes, 72 h pos-transfection. (J) – PDMAEMA/pDNA polyplexes at N/P ratio of 5, 72 h pos-
transfection. (K) – PDMAEMA/pDNA polyplexes at N/P ratio of 10, 72 h pos-transfection. (L) – 
PDMAEMA/pDNA polyplexes at N/P ratio of 20, 72 h pos-transfection. Magnification: 100x for all 
pictures. 
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 In this assay, FuGENE not only yielded the highest transfection efficiency as 
observed for HEK293 cells but also the same peak of transfection at 24 h. Regarding 
PDMAEMA/pDNA polyplexes, the amount of GFP-positive cells detected again had its 
peak at 72 h and the N/P ratio that yielded the highest transfection was 10:1 followed 
by 20:1. The wells in which cells were transfected with PDMAEMA/pDNA polyplexes at 
N/P ratio of 20 displayed very lower cell viabilities in comparison to other treatment 
wells. Altogether, all transfection efficiencies were lower than in the previous assay 
and the gap between FuGENE efficiency and PDMAEMA/pDNA polyplexes efficiency 
has notoriously increased.  
 
Figure 21 summarizes the results of the in vivo transfection assay performed on 
D407 cells. Photos were taken 24, 48 and 72 h pos-transfection for each treatment. 
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Figure 21 – Fluorescence optical microscopy photos taken on D407 cells transfected with 
PDMAEMA/pDNA polyplexes at various N/P ratios (0,5 µg pDNA per 5x10
4
 cells). Each image stands for a 
different treatment at a different time point: (A) – FuGENE lipoplexes, 24 h pos-transfection. (B) – 
PDMAEMA/pDNA polyplexes at N/P ratio of 5, 24 h pos-transfection. (C) – PDMAEMA/pDNA polyplexes 
at N/P ratio of 10, 24 h pos-transfection. (D) – PDMAEMA/pDNA polyplexes at N/P ratio of 20, 24 h pos-
transfection. (E) – FuGENE lipoplexes, 48 h pos-transfection. (F) – PDMAEMA/pDNA polyplexes at N/P 
ratio of 5, 48 h pos-transfection. (G) – PDMAEMA/pDNA polyplexes at N/P ratio of 10, 48 h pos-
transfection. (H) – PDMAEMA/pDNA polyplexes at N/P ratio of 20, 48 h pos-transfection. (I) – FuGENE 
lipoplexes, 72 h pos-transfection. (J) – PDMAEMA/pDNA polyplexes at N/P ratio of 5, 72 h pos-
transfection. (K) – PDMAEMA/pDNA polyplexes at N/P ratio of 10, 72 h pos-transfection. (L) – 
PDMAEMA/pDNA polyplexes at N/P ratio of 20, 72 h pos-transfection. Magnification: 100x for all 
pictures. 
 
 As in the previous assays, FuGENE displayed the same peak of transfection (24 
h) and overall highest efficiency. In this assay, a direct relationship between N/P ratio 
and transfection efficiency was observed and the peak of transfection of 
PDMAEMA/pDNA polyplexes was no exception in this assay, observed at the 72 h 
mark. The cell viability in wells with cells transfected with PDMAEMA/pDNA at N/P 
ratio of 20 has also diminished but in contrast with the other RPE cell line, it was a 
slight decrease. 
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 In general, PDMAEMA/pDNA polyplexes displayed higher transfection 
efficiencies in the HEK293 cell line than in the RPE cell lines. In particular, by 
comparison of the two RPE cell lines, PDMAEMA/pDNA polyplexes yielded higher 
transfection efficiencies on the D407 cell line. 
 
 Transfection efficiencies of PDMAEMA/pDNA polyplexes at various N/P ratios 
(5, 10 and 20) were quantified using FACS analysis to evaluate the influence of N/P 
ratios on the cellular uptake of polyplexes on ARPE-19 cell line. Due to time constrains, 
only this cell line was evaluated. 
The following graphic represents the transfection efficiencies of FuGENE and 
PDMAEMA/pDNA polyplexes on the ARPE-19 cell line. 
 
 
 
Figure 22 – Flow citometry analysis performed on ARPE-19 cells transfected with PDMAEMA/pDNA 
polyplexes at various N/P ratios (1 µg pDNA per 1x10
5
 cells). Error bars represent the standard deviation 
between transfection efficiencies on experimental triplicates. 
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Based on these results, transfection efficiencies of PDMAEMA/pDNA polyplexes 
were low, around 3 and 5% for the N/P ratios of 10 and 20, respectively. The 
transfection efficiency of polyplexes at an N/P ratio of 5 is negligible. Comparatively, 
FuGENE yielded significantly higher efficiencies than PDMAEMA, around 18%. 
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IV – Discussion 
 
The chemical structure of PDMAEMA was verified by 1H NMR and FTIR 
techniques, indicating that at chemical level, the synthesis was successful. However, 
GPC analysis revealed that the polymer had a Mw of 354 kDa with a PDI of 1,31, 
surpassing the proposed Mw of 200 kDa. This deviation does not affect the calculations 
of the N/P ratios because equation 1 takes into account the mass of the polymer 
independently from its Mw. However, there is a direct relation between the 
cytotoxicity of PDMAEMA and its Mw [59]. Consequently, the polymer synthesized in 
this work is more toxic than our initial prediction. 
A potentiometric titration of PDMAEMA revealed that this polymer has a pKa 
around 7. The estimated value indicates that at physiological pH amine groups in 
PDMAEMA are partially deprotonated resulting in a weaker electrostatic interaction 
with DNA in contrast with lower pH values. This result leads to the conclusion that 
while entrapped in an endosome, PDMAEMA binds strongly to DNA whereas in the 
cytosol or intracellular space, this bond weaken permitting some DNA leakage.  
Regarding the cytotoxicity assays, all cell lines tested displayed an inverse 
relationship between cell viability and amount of polymer applied to cell medium. Cell 
viabilities ranged from around 80% (10 µg treatment) to around 40% (30 µg treatment) 
for the HEK293 cell line; around 60% (10 µg treatment) to around 16% (30 µg 
treatment) for the ARPE-19 cell line and around 50% (10 µg treatment) to around 10% 
(30 µg treatment) for the D407 cell line. Moreover, incubation length appears to have 
a decreasing effect on cell viabilities although some was recovered in HEK293 and 
D407 cell lines due to cell proliferation. As a whole, there appears to be a threshold in 
cytotoxicity for all cell lines at 20 µg of polymer mark, in which viabilities decrease 
considerably specially on RPE cell lines. Although D407 cells were treated differently 
than HEK293 and ARPE-19 cells, the results obtained show that PDMAEMA is more 
toxic to the RPE cell lines. This very high toxicity of PDMAEMA towards RPE cells should 
not immediately discard it as a delivery vector because the different amounts of 
polymer used in this assay were largely overestimated and subsequential in vivo 
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transfection assays should not compromise polymer quantities near the ones 
employed in the study. Moreover, the polymer synthesized in this work had a higher 
Mw than predicted resulting in a higher cytotoxicity than initially expected. 
DLS measurements of PDMAEMA/pDNA polyplexes at various N/P ratios 
revealed that an increase in polymer amount (increase in N/P ratio) in polyplex 
formulation yielded particles with decreasing mean diameter (nm) ranging from 266,7 
to 171,3 nm in this experiment. Such finding is attributable to the fact that with an 
increase in polymer or amine quantity, the more positive charges are used to complex 
a fixed amount of pDNA resulting in a more efficient collapse or packaging of the 
genetic material inside the particle and therefore a decrease in polyplex size. On the 
other hand, the more polymer or amine groups used to produce polyplexes, one would 
argue that the repulsion between the positive charges would rise and result in larger 
diameters but the first phenomenon explained overcomes this one. All polyplexes 
studied displayed a PDI below 0,4, which is considered acceptable for DLS 
measurements. A different relation was observed in regard to the zeta potential 
measurements, in which we can establish a direct relationship between N/P ratio and 
magnitude of the surface electrical charge of polyplexes, ranging from 14,4 to 21,3 mV 
in this experiment. This observation can be explained by the fact that the more 
polymer or amines used in the formulation of the particles, the more the excess in 
positive charge in the polyplexes surface and therefore increasingly high positive zeta 
potentials detected. Interestingly, the zeta potentials measured were positive for all the 
ratios studied. These polyplexes would be able to associate with the cell membrane 
through electrostatic interaction with proteoglycans present in the plasma membrane 
surface thus being efficiently internalized in the cell [6]. 
The DNA gel shift assay revealed that for all N/P ratios studied, PDMAEMA was 
able to completely bind and load the genetic material because pDNA migration was 
completely retarded for all N/P ratios in contrast to the naked pDNA loaded as a control 
for this experiment. 
In the assay consisting of particle incubation with DNase I, PDMAEMA/pDNA 
polyplexes at N/P ratios of 1 and 2.5 did not display DNA protection against enzymatic 
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degradation or shielding properties against DNase activity in contrast to polyplexes at 
N/P ratios of 5 and 10. Interestingly, in this experiment the particles were not visible on 
the wells as in the previous assay. Such finding can be explained due to the strong 
electrostatic interaction between the amines in the polymer and the phosphorus 
present in the pDNA, resulting in a severe impairment for ethidium bromide 
intercalation between DNA base pairs therefore resulting in a low fluorescence 
quantum yield after excitation with UV light. This phenomenon can be very significant 
if the pDNA amount complexed in the particles is low, rendering the particles 
undetectable in the gel. In the positive control for DNA degradation there was no 
visible smear resultant from DNA degradation which can be explained by the long 
incubation period with DNase I in this assay. 
A release assay performed on PDMAEMA/pDNA polyplexes at an N/P ratio of 10 
revealed that these particles start releasing genetic material at 72 h post-dialysis, at 
physiological pH. In this assay, the polyplexes were not visible on the wells as in the 
prior assay and the latter explanation can be applied in this case also. 
The fluorescence optical microscopy analysis of cells transfected with FuGENE 
lipoplexes and PDMAEMA/pDNA polyplexes of various N/P ratios (5, 10 and 20) at 24, 
48 and 72 h post-transfection demonstrated that for all cell lines studied, FuGENE 
displayed higher transfection efficiencies than any polyplex formulation. It was 
observed that FuGENE had a peak of transfection 24 h after incubation, with no 
detectable variation along time, whereas the polyplexes presented a peak of 
transfection at 72 h post-transfection for all N/P ratios and cell lines. Complexes of 
FuGENE or PDMAEMA and pDNA display distinct peaks of transfection which appear to 
be a consequence of the difference in cellular internalization mechanism or time these 
complexes spend in endosomes although tests in the intracellular routing of particles 
have to be done to confirm these hypotheses. A direct relationship between N/P ratio 
and transfection efficiency is noticeable for all cell lines except for ARPE-19 in which 
the N/P ratio of 10 appears to have better transfection efficiency than 20 and 5; this 
observation can be attributed to the low cell viabilities in wells with cells transfected 
with PDMAEMA/pDNA polyplexes at an N/P ratio of 20 due to polymer cytotoxicity, 
resulting in a lower amount of GFP-positive cells detected. The relationship between 
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N/P ratio and transfection efficiency can be explained by the better shielding 
properties, higher positive zeta potential and smaller size of the higher N/P ratios 
resulting in a less obstructed cell entry and better protection against pDNA 
degradation resulting in overall higher transfection efficiency. As expected, there were 
clear differences between the transfection efficiencies amongst the cell lines studied 
and, as a whole, HEK293 cells had the highest transfection efficiencies detected 
followed by D407 and ARPE-19, the latter yielding the lowest efficiencies in the assay. 
Transfection efficiencies are known to vary among cell lines and the higher 
proliferation rate of HEK293 cells can partially explain these differences in comparison 
to RPE cell lines. 
Transfection efficiencies of PDMAEMA/pDNA polyplexes at various N/P ratios 
(5, 10 and 20) were further evaluated by flow citometry in regard to the ARPE-19 cell 
line. As expected, the transfection efficiencies were low, around 3 and 5% for the N/P 
ratios of 10 and 20, respectively and negligible for the ratio of 5. Moreover, FuGENE 
yielded significantly higher efficiencies than PDMAEMA, around 18%. At a first glance, 
these results seem to contradict the fluorescence microscopy analysis in which the N/P 
ratio of 10 yielded more GFP-positive cells than the N/P ratio of 20. This can be 
explained by the results of the MTT assay performed on this cell line in which we 
observed an inverse relation between cell viability and amount of polymer applied to 
cell medium. Therefore, fewer live cells were present in samples transfected with 
PDMAEMA/pDNA polyplexes at N/P ratio of 20 in comparison to N/P ratio of 10. Taking 
this into account, the flow citometry may not actually reflect the effectiveness of the 
polymer in terms of cell transfection.  
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V – Conclusion and future perspectives 
 
The synthesis of PDMAEMA by RAFT polymerization was successful at the 
chemical level since the chemical structure of the resulting polymer was verified by 1H 
NMR and FTIR techniques. GPC analysis revealed that this polymer had a Mw of 354 
kDa which was not in agreement with the predicted Mw of 200 kDa. A potentiometric 
titration of PDMAEMA revealed that this polymer has a pKa around 7. The cytotoxicity 
of PDMAEMA was evaluated not only in HEK293 cells but also in RPE cell lines ARPE-19 
and D407 and found to be proportional to polymer amount. These results also showed 
that PDMAEMA is more toxic towards RPE cell lines. However, for the concentration to 
be used in vivo, the cytotoxicity was negligible. PDMAEMA/pDNA polyplexes at N/P 
ratios of 5 and 10 were able to encapsulate and shield DNA from DNase I activity. A 
release assay performed on polyplexes at an N/P ratio of 10 revealed that these 
particles start releasing pDNA at 72 h post-dialysis, at physiological pH. DLS 
measuments revealed nanosized particles with sizes around 213 nm, with sizes 
decreasing with increasing polymer amount and acceptable PDI. The surface charge of 
these polyplexes was found to be positive and with magnitudes around 18 mV by zeta 
potential measurements. Fluorescence microscopy showed all three cell lines 
efficiently transfected with these polyplexes, although to a lesser extent in RPE cells. 
However, further evaluation by flow citometry in regard to the ARPE-19 cell line 
seemed to be inconclusive. 
PDMAEMA is a promising polymer to be used as a non-viral delivery vector for 
gene therapy of the retina given that future work will improve its properties. Future 
work regarding the previously studied polymer should consist on flow citometry 
analysis of D407 cells transfected with PDMAEMA/pDNA polyplexes at various N/P 
ratios (5, 10 and 20) not only to compare the data with the other RPE cell line – ARPE-
19 but also to confirm the results from fluorescence microscopy analysis. With the 
purpose of aiming at the lowest material toxicity and higher transfection efficiencies 
possible, different PDMAEMA molecular weights should be tested as well as di or 
triblocks of PDMAEMA with anionic or zwitterionic polymers. The intracellular routing 
of the polyplexes is also worth to monitor by the aforementioned purposes; to this 
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aim, PDMAEMA should be functionalized with a chemical compound which can act as a 
fluorophore (ex.: rhodamine B) to enable detection of polyplexes inside the cells, over 
time, in a transfection assay. 
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